Sabra Health Care REIT (SBRA) Insider Cusack Buys 8,310 Shares

Sabra Health Care REIT, Inc. (NASDAQ: SBRA) registered another insider transaction as Catherine Cusack acquired 8,310 shares of the company's stock on June 17, 2026, according to a recent filing with the Securities and Exchange Commission.

Catherine Cusack Adds to Her Sabra Holdings

The transaction involved 8,310 shares. Since the transaction price was reported as $0.00, the total value of this specific transaction was listed at $0.00. This is a direct addition to her holdings, coming alongside several similar moves by other company directors.

Sabra Stock Performance and Key Levels

On Friday, Sabra shares were trading at $18.12. The stock has been trading under its 50-day moving average of $20.71, as well as its 200-day moving average of $19.92. This price level is near the lower end of its 52-week trading range, which has a low of $17.17 and a high of $22.77. The company currently has a market valuation of about $5.08 billion. Its price-to-earnings ratio is 76.42, and its forward P/E ratio is 24.53.

Recent Earnings

Sabra reported annual revenue of $863.77 million, with revenue growth coming in at 0.253. The firm has a net margin of 0.07576 and a return on equity of 0.02388. Investors are looking forward to the next quarterly earnings update, which is scheduled for November 4, 2026.

Dividend

Sabra pays a regular dividend to its shareholders. The company has an annual dividend rate of $1.20 per share. At current stock prices, that translates to a dividend yield of 6.04%. The company's dividend payout ratio is 4.6154003.

A Wave of Sabra Insider Purchases on June 17

Catherine Cusack was not the only insider making moves on June 17, 2026. A group of other insiders acquired identical blocks of 8,310 shares. Craig Barbarosh, Jeffrey Malehorn, Michael Foster, Lynne Katzmann, and Ann Kono each picked up 8,310 shares. None of these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. This cluster of buying activity suggests a coordinated timing or compensation-related share award across the board.

What Wall Street Analysts Say About Sabra Stock

Wall Street has been actively updating its outlook on Sabra. On October 13, 2026, UBS maintained its Neutral rating on the stock but lowered its price target to $20.00 from $21.00. On the same day, Barclays maintained its Equal-Weight rating, dropping its target from $23.00 to $21.00. Earlier, on August 31, 2026, Barclays had set a $23.00 target, while Baird maintained a Neutral rating with a $21.00 target. Truist Securities maintained a Buy rating with a $24.00 target on July 22, 2026, and Citizens kept a Market Outperform rating with a $25.00 target. Overall, there are 14 analyst opinions on the stock, with a mean price target of $22.79 and a recommendation key of buy.

About Sabra Health Care REIT

Sabra Health Care REIT owns and invests in real estate properties that serve the healthcare industry. The company operates throughout the United States and Canada, managing a portfolio that includes skilled nursing facilities, senior housing, and other healthcare-related properties. Founded in 2010, the Tustin, California-based firm relies on steady rental income from healthcare operators to fund its operations and dividends.

Keeping an Eye on Sabra's Next Steps

Investors will want to watch how Sabra performs as it approaches its next earnings announcement on November 4, 2026. The recent cluster of insider transactions, combined with analysts adjusting their price targets, shows the active discussion around Sabra's valuation. Future SEC filings will reveal whether insiders continue to add to their positions or if institutional investors start shifting their stakes.